AstraZeneca PLC Financials

AZN Stock  USD 68.26  1.93  2.91%   
Based on the measurements of operating efficiency obtained from AstraZeneca PLC's historical financial statements, AstraZeneca PLC ADR is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.
With this module, you can analyze AstraZeneca financials for your investing period. You should be able to track the changes in AstraZeneca PLC individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past AstraZeneca PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AstraZeneca PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in AstraZeneca PLC's assets may result in an increase in income on the income statement.
Evaluating AstraZeneca PLC's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of AstraZeneca PLC's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the AstraZeneca PLC's relative financial performance

Chance Of Distress

Less than 17

 
100  
 
Zero
Low
AstraZeneca PLC ADR has less than 17 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for AstraZeneca PLC stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, AstraZeneca PLC's odds of distress score SHOULD NOT be confused with the real chance of AstraZeneca PLC ADR filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as AstraZeneca is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include AstraZeneca PLC's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in AstraZeneca PLC's official financial statements usually reflect AstraZeneca PLC's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AstraZeneca PLC ADR. For example, before you start analyzing numbers published by AstraZeneca accountants, it's critical to develop an understanding of what AstraZeneca PLC's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of AstraZeneca PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AstraZeneca PLC's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AstraZeneca PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AstraZeneca PLC ADR. Please utilize our Beneish M Score to check the likelihood of AstraZeneca PLC's management manipulating its earnings.

AstraZeneca PLC Company Summary

AstraZeneca PLC competes with Agilent Technologies, Mustang Bio, Moleculin Biotech, Seres Therapeutics, and Madrigal Pharmaceuticals. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 83100 people.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS0463531089
CUSIP046353108 98934D106
LocationUnited Kingdom
Business Address1 Francis Crick
SectorPharmaceuticals
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.astrazeneca.com
Phone44 20 3749 5000
CurrencyUSD - US Dollar
You should never invest in AstraZeneca PLC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of AstraZeneca Stock, because this is throwing your money away. Analyzing the key information contained in AstraZeneca PLC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

AstraZeneca PLC Key Financial Ratios

Generally speaking, AstraZeneca PLC's financial ratios allow both analysts and investors to convert raw data from AstraZeneca PLC's financial statements into concise, actionable information that can be used to evaluate the performance of AstraZeneca PLC over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that AstraZeneca PLC ADR reports annually and quarterly.

AstraZeneca Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.
AstraZeneca PLC ADR is rated second in return on equity category among related companies. It is number one stock in gross profit category among related companies fabricating about  228,465,473,146  of Gross Profit per Return On Equity. . Comparative valuation analysis is a catch-all model that can be used if you cannot value AstraZeneca PLC by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AstraZeneca PLC's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.

AstraZeneca PLC ADR Systematic Risk

AstraZeneca PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AstraZeneca PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on AstraZeneca PLC ADR correlated with the market. If Beta is less than 0 AstraZeneca PLC generally moves in the opposite direction as compared to the market. If AstraZeneca PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AstraZeneca PLC ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AstraZeneca PLC is generally in the same direction as the market. If Beta > 1 AstraZeneca PLC moves generally in the same direction as, but more than the movement of the benchmark.

About AstraZeneca PLC Financials

What exactly are AstraZeneca PLC Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include AstraZeneca PLC's income statement, its balance sheet, and the statement of cash flows. Potential AstraZeneca PLC investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may use each financial statement separately, they are all related. The changes in AstraZeneca PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AstraZeneca PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze AstraZeneca PLC Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as AstraZeneca PLC is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of AstraZeneca has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if AstraZeneca PLC's financials are consistent with your investment objective using the following steps:
  • Review AstraZeneca PLC's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand AstraZeneca PLC's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare AstraZeneca PLC's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if AstraZeneca PLC's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

AstraZeneca PLC Thematic Clasifications

AstraZeneca PLC ADR is part of Compulsion investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol
CompulsionView
This theme covers Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. Get More Thematic Ideas

AstraZeneca PLC March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of AstraZeneca PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AstraZeneca PLC ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of AstraZeneca PLC ADR based on widely used predictive technical indicators. In general, we focus on analyzing AstraZeneca Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AstraZeneca PLC's daily price indicators and compare them against related drivers.
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for AstraZeneca Stock analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.